Introduction {#Sec1}
============

Female sex has been shown to be a risk factor for the development of adverse drug reactions (ADRs) \[[@CR1]--[@CR3]\]. Adverse effects to a number of drugs appear to be more frequent and severe in women than in men \[[@CR4], [@CR5]\], and this is in line with the evidence that eight out of 10 drugs dropped out from the US market were responsible for more ADRs in women than in men \[[@CR6]\]. The impact of pharmacodynamic and pharmacokinetic differences between sexes as well as of the physiological/hormonal status of women has been discussed. Furthermore, it has been pointed out that risk factors for ADRs, such as polytherapy, aging, and depression, are more frequent in women \[[@CR1]--[@CR3], [@CR7], [@CR8]\].

Confounding factors biasing clinical trials results include small numbers of women, as well as weight or body mass index (BMI) and hormonal status not being considered \[[@CR9]\]. Therefore, the US Food and Drug Administration (FDA) issued a guideline calling for the inclusion of women into early phases of clinical trials and the consideration of the effects of female physiology, such as hormones, during the study of drugs. Indeed, the optimization of therapy requires gender attention.

To our knowledge, no previous study analyzed the sex-specific incidence rate of AEs during CsA treatment of plaque psoriasis in real life. The GENDER ATTENTION study was designed with the aim of investigating, in Italian dermatological practice, the influence of gender and menopause on the incidence of AEs during cyclosporine (CsA) treatment. The study was conducted on a population of patients with plaque psoriasis, a disease that is rather equally distributed among genders \[[@CR10]\].

Methods {#Sec2}
=======

Study Subjects {#Sec3}
--------------

Adult (age at least 18 years) male and female outpatients diagnosed with plaque psoriasis were enrolled, either naïve or previously treated with CsA, who had been undergoing a new CsA administration course for at most 30 days before, or about to start it within 14 days after study enrollment, with any therapeutic regimen according to the investigator's choice. Patients were divided into four cohorts of patients: fertile women (cohort 1) and age-matched men (cohort 2); women in menopause (cohort 3) and age-matched men (cohort 4). In order to evaluate differences between genders, men were planned to be matched to women in a 1:2 ratio into the following age groups: 18--34; 35--44; 45--54; 55+ years. Menopausal status was defined as the presence of amenorrhea for at least 12 months.

All subjects gave their informed consent for participation in the study. The study protocol was reviewed by the independent ethics committee (IEC) or institutional review board (IRB) of each center. The study was carried out in accordance with the approved applicable guidelines.

Study Design {#Sec4}
------------

This was a multicenter, prospective, observational, cohort study. After enrollment, patients were followed for a period of 2--6 months. Two study visits were planned: one enrollment visit and one follow-up visit at CsA discontinuation or at the end of follow-up or withdrawal from the study, whichever came first (min 2 months, max 6 months).

The primary objective was to evaluate the difference in adverse event (AE) incidence rate between fertile and postmenopausal women and age-matched men, during CsA treatment. Secondary objectives were to compare AE severity between genders, to describe AEs in relation to patient hormonal levels, and to assess overall patient satisfaction, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM) \[[@CR11]\].

At the enrollment visit, sociodemographic data and medical history were collected, the Psoriasis Area and Severity Index (PASI) was evaluated, and the menopausal status was assessed in women on the basis of absence for at least the last 12 months of the menstrual cycle. Blood samples were drawn for hormonal level measurement: E~2~, FSH, LH, dehydroepiandrosterone (DHEA) sulfate, cortisol, testosterone; in fertile women blood had to be drawn within 7 days from the start date of the menstrual cycle. All enrolled patients were given a diary to note CsA treatment, concomitant medications, and AEs that occurred between baseline and the follow-up visit. At the follow-up visit, data on psoriasis treatment, other concomitant medications, and AEs were collected, and PASI was re-evaluated. The TSQM was administered at the follow-up visit.

As this was a non-interventional study, participants received CsA as per patients' needs and local clinical practice, and there were no constraints about concomitant treatment.

Sample Size {#Sec5}
-----------

The number of available and affordable participants for this study was fixed at 1200 patients. We planned to enroll 400 fertile women and 200 age-matched men as well as 400 women in menopause and 200 age-matched men. Starting from the fixed sample size of 1200 enrolled patients, the minimum effect size that can be detected was computed. The information needed to calculate the minimum detectable incidence rate ratio (IRR), i.e., incidence rate of side effects in men and in fertile/postmenopausal women, was not available, since incidence rates have never been studied in the manner intended in this study. According to the study steering committee's opinion, on the basis of the Italian clinical experience with the doses used in dermatology that are largely beneath those considered at risk of AEs, an AE incidence rate of about 8 per 100 person-months was to be expected. Assuming that 20% of patients are not evaluable because of missing values or dropout, 960 subjects were expected to be included in the analyses: 320 fertile women and 160 age-matched men, and 320 women in menopause and 160 age-matched men. Assuming a type I error rate of 5% with an allocation ratio of 1:2 (men vs. women) for each comparison, the minimum detectable IRR was computed as a function of the reference incidence rate (incidence rate from 4 to 16 side effects per 100 person-months) and of the average follow-up duration (3, 4, and 5 months were considered). According to these assumptions, the minimum detectable IRR ranged from 1.24 (for an expected reference incidence rate of 16 side effects per 100 person-months and an average follow-up duration of 5 months) to 1.69 (for an expected reference incidence rate of 4 side effects per 100 person-months and an average follow-up duration of 3 months).

Statistical Analysis {#Sec6}
--------------------

The sample of patients included in the study was described in terms of sociodemographic and clinical characteristics at baseline, CsA treatment features, and concomitant medications. The proportion of patients experiencing at least one AE was computed in each cohort, overall and by event type. Differences among cohorts were assessed by means of Chi-squared tests. Grade of AEs was evaluated as well by comparing the number of grade 1--2 vs. grade \>2 events between patient cohorts (Chi-squared tests).

Treatment exposure was calculated as the number of months elapsed from the start to the end of the CsA treatment course or to the follow-up visit/withdrawal from the study. The incidence rate was calculated as the number of AEs occurred during the exposure period divided by the total person-time at risk of side effects. Comparisons of rates between fertile women vs. age-matched men, postmenopausal women vs. age-matched men, and fertile vs. postmenopausal women were performed by calculating IRRs and their 95% confidence intervals.

IRRs of AEs between two cohorts were estimated using a Poisson regression model. The response variable was the count of AEs observed during the exposure period, while the covariate was the categorical variable that identified the cohort. The logarithm of person-time in months was included in the model with coefficient constrained to 1 (i.e., offset). In order to take into account data overdispersion, the scale parameter was estimated as the square root of the ratio between deviance and degrees of freedom. Moreover, multivariate Poisson regression models including potential confounder as covariate (one at a time) were provided.

Finally, hormone levels were described by occurrence of AEs in each cohort. Wilcoxon--Mann--Whitney tests were applied to evaluated differences between patients with and without AEs for some identified hormones.

Results {#Sec7}
=======

Overall, 969 patients were enrolled into the study; 76 patients were excluded because of unavailability of the exposure period and four because they did not meet the inclusion criteria; 59 voluntarily withdrew or were lost to follow-up; 830 completed baseline evaluation (Fig. [1](#Fig1){ref-type="fig"}). During follow-up, one patient died for causes not related to CsA according to the investigator's judgment, and two withdrew for organizational reasons. Regarding male to female ratio, after a few months from enrollment start it was noticed that the 1:2 ratio was not achievable. This may be explained by the fact that women are less willing to participate in studies than men for reasons of time availability. Thus, male cohorts were increased in order to maximize the number of patients included in the analyses. In each age class (18--34, 35--44, 45--54, 55+), the proportion of fertile and postmenopausal women was computed and an equal proportion of randomly selected men was matched to each group (Table [1](#Tab1){ref-type="table"}). Finally, the safety analysis included 336 fertile women and 253 age-matched men as well as 182 postmenopausal women and 118 age-matched men. Sociodemographic and baseline features of each study cohort are summarized in Table [1](#Tab1){ref-type="table"}. Participants were 97.4% Caucasian with no differences between cohorts. In cohort 3, the median time since menopause was 66 months. At study entry, 28.6% of patients showed at least one concomitant disease. That proportion was higher in the older cohorts, but no significant differences were observed between women and age-matched men cohorts (22.3% in cohort 1, 19.0% in cohort 2, 46.2% in cohort 3, and 39.8% in cohort 4). The most common concomitant disease at baseline in all cohorts was hypertension: 3.3% and 5.1% in cohorts 1 and 2, respectively, and 21.4% and 16.9% in cohorts 3 and 4, respectively. In the enrolled sample no patient was naïve to CSA treatment. A treatment course of 7 days a week for about 17--20 weeks was the most used CsA treatment regimen. During this period, patients received up to three doses of cyclosporine every day (11.6% one, 79.0% two, and the remaining three doses). The average daily dose (SD) of cyclosporine was 3.3 (0.8) mg/kg in cohort 1, 3.2 (0.8) mg/kg in cohort 2, 3.1 (0.7) mg/kg in cohort 3, and 3.0 (0.9) mg/kg in cohort 4. Topical therapies were the most common concomitant treatment in all cohorts with a percentage ranging from 28.6% in cohort 3 to 41.5% in cohort 4. Among other treatments for psoriasis, 1.7% of patients received phototherapy and 4.4% systemic therapies. Concomitant hormonal treatments were used almost exclusively in cohort 1, with 9.5% of fertile women taking the contraceptive pill, and a small percentage receiving hormone replacement therapy (1.8%).Fig. 1Patient disposition. The figure shows the number of patients considered for the analysis and who dropped out. Reasons for non-evaluability or dropout could be multiple Table 1Sociodemographic and disease baseline featuresVariableCohort 1: fertile womenCohort 2: age-matched men (to fertile women)Cohort 3: postmenopausal womenCohort 4: age-matched men (to postmenopausal women)*N*336253182118Age (years), mean (SD)35.56 (9.03)(*p* = 0.039)^§^\
37.06 (8.78)57.13 (5.68)(*p* = 0.011)^\#^\
55.46 (6.07)Age group, *n* 18--341519400 35--4412411011 45--5460485846 55+1112371Education, *n* (%)\*(*p* = 0.099)^§^(*p* = 0.234)^\#^ None0 (0.0)0 (0.0)2 (1.1)1 (0.8) Primary school8 (2.4)10 (4.0)35 (19.2)15 (12.7) Lower secondary90 (26.8)79 (31.2)62 (34.1)51 (43.2) Upper secondary175 (52.1)133 (52.6)60 (33.0)40 (33.9) Bachelor degree54 (16.1)25 (9.9)18 (9.9)8 (6.8)Caucasian race, *N* (%)328 (97.6%)(*p* = 0.395)^§^\
243 (96.0%)178 (97.8%)(*p* = 0.453)^\#^\
117 (99.2%)Age at diagnosis (years), mean (SD)23.81 (10.59)(*p* = 0.371)^§^\
24.87 (10.18)40.85 (13.61)(*p* = 0.813)^\#^\
40.74 (13.01)Disease duration (years), mean (SD)12.13 (10.08)(*p* = 0.366)^§^\
12.58 (9.11)16.75 (12.97)(*p* = 0.120)^\#^\
15.12 (10.82)PASI at enrollment, *n* (%)\*(*p* = 0. 836)^§^(*p* = 0.272)^\#^ ≤20258 (84.6)192 (83.5)132 (81.5)90 (80.4) 21--2935 (11.5)30 (13.0)22 (13.6)20 (17.9) ≥3012 (3.9)8 (3.5)8 (4.9)2 (1.8)Months from CSA start, mean (SD)40.76 (42.19)(*p* = 0.772)^§^\
41.58 (39.97)48.39 (52.60)(*p* = 0.140)^\#^\
37.74 (47.02)No. of previous CSA cycles, mean (SD; min--max)2.09 (1.71; 1--10)(*p* = 0.684)^§^\
2.19 (2.07; 1--14)1.98 (1.44; 1--7)(*p* = 0.0684)^\#^\
2.60 (2.08; 1--10)No. of days of CSA treatment, mean (SD)130.00 (54.13)(*p* = 0.009)^§^\
141.40 (51.28)122.59 (54.62)(*p* = 0.007)^\#^\
140.0 (54.89)The *t* test for equal variances was considered for continuous variables, Chi-squared test for categorical variables\* Percentages are computed on the basis on patients with available data^§^Fertile women vs. age-matched men (to fertile women)^\#^Postmenopausal women vs. age-matched men (to postmenopausal women)

Overall, 302 patients reported at least one AE (34.0%). The percentage of patients with AEs was 31.3% in cohort 1, 29.6% in cohort 2, 42.3% in cohort 3, and 38.1% in cohort 4 (Fig. [2](#Fig2){ref-type="fig"}). Incidence and type of AEs are reported in Table [2](#Tab2){ref-type="table"}. A significant difference was observed between fertile and postmenopausal women (Chi-squared *p* value 0.0118), but no statistically significant differences were observed in fertile and postmenopausal women compared to age-matched men (Chi-squared *p* value 0.675 and 0.472, respectively). The IRR of fertile women compared to age-matched men was 1.37 (95% CI 1.00--1.86), while IRR comparing postmenopausal women vs. age-matched men was 1.18 (95% CI 0.78--1.79). Thus, AE incidence rate was about 37% higher in fertile women than in age-matched men and about 18% higher in postmenopausal women than in age-matched men, but no significant differences between female and male cohorts were observed. IRR of fertile vs. postmenopausal women was 0.67 (95% CI 0.49--0.92), reaching statistical significance. Severity of AEs, according to the Common Technology Criteria for Adverse Events (CTCAE), is summarized in Table [3](#Tab3){ref-type="table"}. AEs were mild (grade 1, 47.6--60.2%) or moderate (grade 2, 35.2--40.1%) in the great majority of patients of all cohorts. However, a significant difference between severity of the AE (grade 1--2 vs. \>2) and patient's cohort was observed, with postmenopausal women having less low grade AEs and more grade 3--4 AEs compared to fertile women (87.7% vs. 95.5% of AEs experienced by postmenopausal and fertile women were grade 1--2, respectively, while 12.3% vs. 4.5% were grade 3--4, *p* = 0.0005). Considering individual AEs, hypertension was significantly less reported in both cohort 1 and 2 (younger females and males) compared to cohort 3 and 4 (older females and males) respectively (*p* = 0.002 and *p* = 0.02, respectively). Once adjusted for age, education level, BMI, psoriasis duration, presence of concomitant diseases, presence of concomitant treatments, and baseline PASI (considered one at a time), IRR comparing fertile women versus age-matched men did not change (min 1.31, max 1.38), while adjusting for time elapsed from the start of CsA treatment, IRR decreased to 1.09. Similarly, comparing women in menopause versus age-matched men, IRR did not change adjusting for age, education level, BMI, presence of concomitant diseases, and presence of concomitant treatments (considered one at a time) (min 1.17, max 1.23), while an increase, though not statistically significant, was obtained adjusting for other potential confounders, such as duration of psoriasis (1.35), time elapsed from CsA treatment start (1.37), and PASI (1.41). Anyway, variations in IRR due to controlling for potential confounders seem to be negligible.Fig. 2Proportion of patients with at least one adverse event by patient cohort, overall, and by system organ class (the most frequent ones are displayed). For each cohort, proportions are computed as the ratio between the number of patients experiencing at least one adverse event during the exposure period and the total number of evaluable patients. The number of evaluable patients was 336 for fertile women (cohort 1), 253 for age-matched men (cohort 2), 182 for postmenopausal women (cohort 3), and 118 for age-matched men (cohort 4). The *p* value of the Chi-squared test between female cohort (fertile/postmenopausal) and experience of adverse events (yes/no) is shown as well Table 2Incidence of adverse events by preferred term (≥1% incidence in any cohort)Patients with AE, *n* (%)Cohort 1Cohort 2Cohort 3Cohort 4Headache38 (11.3)20 (7.9)21 (11.5)13 (11.0)Hypertension12 (3.6)19 (7.5)19 (10.4)18 (15.3)Fatigue14 (4.2)14 (5.5)12 (6.6)4 (3.4)Muscle cramps11 (3.3)7 (2.8)15 (8.2)8 (6.8)Nausea18 (5.4)7 (2.8)8 (4.4)6 (5.1)Abdominal pain14 (4.2)6 (2.4)11 (6.0)7 (5.9)Muscle weakness13 (3.9)6 (2.4)9 (4.9)7 (5.9)Paresthesia12 (3.6)9 (3.6)5 (2.7)6 (5.1)Myalgia9 (2.7)5 (2.0)11 (6.0)3 (2.5)Diarrhea12 (3.6)2 (0.8)8 (4.4)5 (4.2)Tremor9 (2.7)2 (0.8)10 (5.5)4 (3.4)Gingival hyperplasia10 (3.0)5 (2.0)4 (2.2)5 (4.2)Hypertrichosis10 (3.0)4 (1.6)8 (4.4)2 (1.7)Insomnia4 (1.2)8 (3.2)6 (3.3)2 (1.7)Visual disturbances5 (1.5)2 (0.8)7 (3.8)4 (3.4)Agitation7 (2.1)2 (0.8)5 (2.7)0Vomit3 (0.9)2 (0.8)5 (2.7)1 (0.8)Weight gain3 (0.9)2 (0.8)6 (3.3)0Hyperlipidemia1 (0.3)5 (2.0)2 (1.1)2 (1.7)Menstrual disorders8 (2.4)--1 (0.5)--Vascular events3 (0.9)03 (1.6)1 (0.8)Arthralgia2 (0.6)2 (0.8)2 (1.1)1 (0.8)Renal dysfunction1 (0.3)3 (1.2)02 (1.7)Confusion2 (0.6)1 (0.4)2 (1.1)0Disorientation1 (0.3)03 (1.6)0Edema1 (0.3)1 (0.4)2 (1.1)0Hepatic laboratory alterations01 (0.4)2 (1.1)0Swollen limbs001 (0.5)2 (1.7) Table 3Severity of adverse events (AEs) according to CTCAE v. 3.0Severity of AEsCohort 1Cohort 2Cohort 3Cohort 4*n* (%)*n* (%)*n* (%)*n* (%)1200 (60.2)113 (56.8)120 (47.6)88 (55.7)2117 (35.2)70 (35.2)101 (40.1)60 (38.0)315 (4.5)15 (7.5)28 (11.1)9 (5.7)401 (0.5)3 (1.2)050001 (0.6)Chi-squared test between severity of adverse events (CTCAE v. 3.0 grade 1--2/\>2) and fertile/postmenopausal women, *p* = 0.0005Chi-squared test between severity of adverse events and fertile women/matched men and postmenopausal women/matched men, respectively, not significantPercentages are computed from the number of adverse events that occurred in each patient cohort*CTCAE* common technology criteria for adverse events

Hormone levels stratified by patients with and without at least one AE in the four cohorts are reported in Table [4](#Tab4){ref-type="table"}. Hormone levels in postmenopausal women confirmed their menopausal status. As expected, in postmenopausal women E~2~ levels were reduced to men's levels, while conversely FSH and LH levels were significantly higher than in fertile women. Median FSH levels were significantly higher in postmenopausal women reporting no AEs compared to those with at least one AE (Wilcoxon--Mann--Whitney test *p* = 0.0284). DHEA sulfate levels were consistently lower in postmenopausal women than in fertile women and in men, but do not seem to correlate with occurrence of AEs. Among men, DHEA sulfate levels were about 10% higher in those with no AEs vs. those with AEs. Cortisol levels were rather homogeneous among cohorts, but were slightly significantly higher in postmenopausal women with no AE (Wilcoxon--Mann--Whitney test *p* = 0.0274). Median testosterone levels were a little higher (NS) in both postmenopausal women and men with no AE compared to those reporting AEs. Overall treatment satisfaction, measured by TSQM, was rather high (mean score from 67 to 91 for all items considering all patients) with no differences between cohorts, except for a slightly lower side effects score in postmenopausal women, consistent with the higher AE incidence rate in this cohort.Table 4Hormone levels in the different study populations, stratified by presence or absence of adverse effects (AEs)HormoneWith no AEsWith ≥1 AEs*p* valueFertile women 17-beta-estradiol (pg/mL)32.71 (21.84; 54.92)33.17 (19.60; 49.78) FSH (mIU/mL)6.68 (4.55; 9.59)6.83 (4.71; 10.74) LH (mIU/mL)9.36 (6.22; 12.91)8.69 (5.11; 12.56) DHEA sulfate (mg/mL)147.00 (94.00; 228.00)157.50 (108.00; 256.50)0.2683 Cortisol (mg/dL)12.05 (8.32; 17.61)11.18 (7.85; 15.34) Testosterone (ng/dL)51.00 (34.00; 68.00)55.50 (44.00; 68.00) Free testosterone (pg/mL)1.06 (0.46; 2.20)1.10 (0.56; 2.55)Postmenopausal women 17-beta-estradiol (pg/mL)16.39 (11.06; 27.67)14.99 (10.81; 31.18) FSH (mIU/mL)60.59 (45.67; 91.05)54.01 (38.70; 79.76)0.0284 LH (mIU/mL)42.05 (33.11; 53.11)42.51 (30.41; 52.72) DHEA sulfate (mg/mL)83.00 (47.00; 120.00)71.00 (43.00; 126.00)0.4575 Cortisol (mg/dL)12.85 (9.49; 17.02)10.69 (7.41; 14.96)0.0274 Testosterone (ng/dL)44.50 (31.00; 61.50)42.00 (28.00; 57.00)0.1755 Free testosterone (pg/mL)0.78 (0.37; 1.52)0.51 (0.13; 1.12)Men 17-beta-estradiol (pg/mL)19.86 (13.65; 30.06)19.26 (14.89; 34.23) FSH (mIU/mL)4.22 (2.98; 6.49)4.87 (3.32; 6.36) LH (mIU/mL)7.67 (5.48; 10.20)6.99 (5.36; 10.00) DHEA sulfate (mg/mL)197.00 (123.00; 341.00)181.00 (116.00; 277.00) Cortisol (mg/dL)11.42 (8.73; 15.72)11.25 (8.44; 15.62) Testosterone (ng/dL)404.00 (319.00; 513.00)387.00 (288.00; 463.00)0.0827 Free testosterone (pg/mL)9.50 (6.30; 14.54)9.61 (5.33; 14.12)Values are expressed as median (25th percentile; 75th percentile)Wilcoxon test was calculated to test clinically relevant differences

Discussion {#Sec8}
==========

To our knowledge, this is the first large clinical study specifically designed to assess potential gender- and hormone-related differences in AEs associated with CsA treatment. Since CsA dosage is based on weight, we considered it a "clean" drug model to analyze the real difference between genders \[[@CR12]\]. Psoriasis was chosen as disease model because it is usually treated with one systemic drug at a time only. As this was a non-interventional study, participants received CsA as per individual needs and local clinical practice, and there were no constraints about concomitant treatment.

Our results show a slightly higher IRR of AEs in fertile women compared to age-matched men (+37%) and in postmenopausal women compared to age-matched men (+18%), though both differences failed to show statistical significance. These findings are confirmed even when adjusted for potential confounders. Several published data report an association between female sex and frequency of ADRs \[[@CR13]--[@CR22]\], which has been hypothesized to be due to the higher prevalence of headache, migraine, and musculoskeletal pain in women, the higher prevalence of women among the elderly population, and the greater attention women pay to their health status. Moreover, menstrual cycles, pregnancy, and menopause are likely to have a relevant impact on pharmacokinetics and pharmacodynamic of drugs \[[@CR23]\]. Several sex-related factors, including hormonal status and genetics, have been proposed to explain why women experience more ADRs in response to viral vaccines and antiviral drugs \[[@CR24]\]. However, in our study, we found only a small non-significant difference between genders, which may be explained by the fact that CsA, unlike the majority of current drugs, is given on a body weight basis, which reduces one major gender impact. Actually, women are generally treated with doses that essentially reflect the results obtained by trials carried out mainly in men, and this has been hypothesized as one important reason for the higher incidence of drug adverse effects observed in women. Pharmaceutical companies should pay more attention, from the early drug development phases, to find out gender-appropriate doses.

On the other hand, in our study a significant difference between fertile and postmenopausal women emerged, which suggests that hormonal status and age may affect CsA tolerability. Also differences between men and women appear to be higher when hormonal differences exist, i.e., in the fertile age. Menopause is associated with changes not only in hormonal status but also in inflammatory factors, including cytokines, that have shown an impact on drug response \[[@CR24], [@CR25]\]. It can be hypothesized that menopause might thus have some influence also on drug tolerability. Higher cortisol and testosterone levels in postmenopausal women with no AEs might suggest a potential slightly protective effect of these hormones (Table [4](#Tab4){ref-type="table"}; Fig. [3](#Fig3){ref-type="fig"}). No other clinically relevant associations were found between hormone levels and incidence of AEs. During menopause FSH levels are normally high; in fact, FSH levels support the diagnosis of menopause: this was also observed in our sample. We do not expect that FSH could have played any protective role within postmenopausal women.Fig. 3Cortisol levels in postmenopausal women with and without adverse events. The *box plot* of cortisol level (mg/dL) in postmenopausal women who experienced at least one adverse event (*N* = 66) and who did not experience any adverse events (*N* = 88) during the exposure period is shown. The*upper* and*lower edges* of the *box* represent the 75th and the 25th percentile, respectively. The *line* and the *plus symbol* inside the box correspond to the median and mean value, respectively. *Whiskers* are limited by the maximum observation below upper fence (*upper limit*) and the minimum observation (*lower limit*).*Small squares* above the upper edge of the whiskers represent observations beyond the upper fence, defined as 1.5 (interquartile range) above the 75th percentile

A previous gender analysis in psoriatic patients, the PSYCHAE study, showed that Italian dermatologists seem to have the same approach in treating male and female patients with psoriasis, although women might warrant more attention to their psychological distress, which was higher than in men \[[@CR26]\]. The GENDER ATTENTION study further suggests that greater attention in treating psoriatic patients with CsA should be paid to older patients and postmenopausal women.

Although this was not a study objective, it is worth mentioning that our results show a reassuring safety and tolerability profile of CsA, at the doses used to treat psoriasis in Italian common dermatological practice, with the great majority of patients of all cohorts having AEs of low or moderate severity. The most commonly occurring AE was headache, which showed higher incidence than expected from the known CsA tolerability profile, but it has to be considered that this type of event is quite common and can occur for lots of reasons. Among the most common CsA side effects \[[@CR12]\], only hypertension was rather common in all our cohorts, significantly more so in older cohorts of both genders, this being explained by the fact that blood pressure tends to increase with age and prevalence of hypertension is higher among aged people. Hypertension is also expected according to previous literature \[[@CR12]\]. The low overall proportion of patients with renal dysfunction is reassuring in terms of CsA safety profile and seems to confirm that renal dysfunction occurs only in predisposed, susceptible subjects. Also positive is the occurrence of hyperkalemia in only one patient. Paresthesia, gingival hyperplasia, and hypertrichosis are well-described CsA side effects, which occurred in our cohorts in a low proportion of patients, from 1.6% to 5.1%. In terms of TSQM, our patients showed a rather high level of treatment satisfaction, especially in terms of convenience and tolerability, with very little differences among cohorts.

This study suffers from methodological limitations, first of all because its observational design did not allow one to include strictly homogeneous patients and treatment regimens. Moreover, study patients were neither newly diagnosed nor naïve to study treatment, thereby by representing a useful example of real-world-based evidence. An important point to be taken into account is that, as a result of the real-world setting in which we conducted the study, we could not control for tobacco, alcohol, or drug use that may interact with CYP3A4 isoenzymes that are involved in CsA metabolism, thus influencing plasma CsA levels. It is known that CSA bioavailability can be influenced by many variables, not only tobacco or specific drugs, so it is not possible to keep them controlled in the study, especially in the real-world setting, where clinicians are free to treat patients according to routine clinical practice \[[@CR27]\]. Other possible sources of bias could have been disease and treatment duration, which could have acted as confounders in the association between gender and occurrence of AEs, even though, to partially overcome this bias, IRRs were calculated also after adjusting for such factors. Another possible limitation could be due to the fact that the GENDER study followed patients only up to the end of the ongoing treatment course. The limited follow-up makes our results preliminary and worth being confirmed either. On the other hand, we think that the GENDER ATTENTION study represents a useful example of real-world evidence-based medicine: the observational prospective design allowed us to observe a large cohort of patients treated in a routine clinical practice setting.

Conclusions {#Sec9}
===========

We believe that the GENDER ATTENTION study may play a role in the context of gender in Italian medicine, being the first study that analyzed sex-specific incidence rate of AEs during CsA treatment of plaque psoriasis in the real life. The results showed a trend towards more side effects in women compared to age-matched men, and age- and hormonal status-related differences in tolerability, with older patients and postmenopausal women reporting a higher incidence of AE. ADRs represent a source of great health concern as well as of increased health and social costs, in terms of hospitalizations, length of hospital stay, loss of productivity, and need to be investigated further and more in depth. This study shed some preliminary light on possible sex- and hormone-related influences on drug tolerability. A better understanding of the impact of gender and hormones on drug responses may enable clinicians to tailor pharmacological treatments to individual subjects or specific classes of patients.
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